Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Clorprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.85 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 0.85 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorprenaline SCHEMBL250611 | 0.92 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL29483933 | 0.92 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL30394245 | 0.91 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL406791 | 0.91 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL2852861 | 0.89 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL45370 | 0.89 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL15568417 | 0.89 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL29417577 | 0.89 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL2852860 | 0.88 | ADRB2 (0.90) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL1650012 | 0.88 | ADRB2 (0.90) | ADRB2ADRB1CYP2D6HIF1ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835520-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20190030010-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10117861-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-06 | — | — | US | disclosed |
| EP-3150577-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| EP-2980072-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20180042908-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9820980-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| EP-2762466-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9676719-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-3150577-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060014835-A1 | Therapeutic agent for chronic obstructive pulmonary disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1552824-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117861-B2 | Phenyl derivative | S1PR2, S1PR1, S1PR3 | ADRB2 16/4885ADRB1 21/4885ADRB3 74/4885 |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | ADRB2 44/4885ADRB1 184/4885ADRB3 199/4885 |
| US-20180042908-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | ADRB2 16/4885ADRB1 21/4885ADRB3 74/4885 |
| US-20190030010-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | ADRB2 16/4885ADRB1 21/4885ADRB3 74/4885 |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | PDCD4, PDE4B, IRAK4 | ADRB2 976/4885ADRB1 522/4885ADRB3 1911/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | ADRB2 337/4885ADRB1 461/4885ADRB3 567/4885 |
| US-10835520-B2 | Phenyl derivative | S1PR2, S1PR1, S1PR3 | ADRB2 16/4885ADRB1 21/4885ADRB3 74/4885 |
| US-20060014835-A1 | Therapeutic agent for chronic obstructive pulmonary disease | HAO2, MMP8, HCAR2 | ADRB2 727/4885ADRB1 1590/4885ADRB3 1347/4885 |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | ADRB2 500/4885ADRB1 249/4885ADRB3 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.